1 Surveillance for acute viral hepatitis - United States, 2007

2 Synthesis and biological evaluation of (1,2,4)triazole[4,3-a]pyridine derivatives as potential therapeutic agents for concanavalin A-induced hepatitis.

3 Gold nanoparticles and hepatitis B virus

4 Prognostic profile of patients with non-viral hepatocellular carcinoma: A comparative study with hepatitis C virus-related hepatocellular carcinoma using data mining analysis.

5 Cost-effectiveness of direct anti-viral agents for hepatitis C virus infection and a combined intervention of syringe access and medication assisted therapy for opioid use disorders in an injection drug use population.

6 How expensive may drugs be? The example of hepatitis C drugs

7 The average effective dose of 4-amino-5-(furan-2-yl)-4H-1 ,2,4-triazole-3-thiol in experimental hepatitis

8 Prediction and Staging of Hepatic Fibrosis in Children with Hepatitis C Virus: A Machine Learning Approach.

9 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

10 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

11 Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

12 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

13 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

14 Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

15 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

16 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

17 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

18 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

19 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

20 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

21 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

22 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

23 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

24 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

25 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

26 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

27 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

28 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

29 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

30 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

31 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

32 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

33 Approaches to hepatitis C treatment and cure using NS5A inhibitors

34 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

35 Current treatment of choice for chronic hepatitis C infection

36 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

37 New approaches in the management of chronic hepatitis B: role of tenofovir

38 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

39 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

40 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

41 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

42 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

43 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

44 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

45 Profile of sofosbuvir/velpatasvir/voxilaprevir in the treatment of hepatitis C

46 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience [Corrigendum]

47 In Silico Screening of Aptamers Configuration against Hepatitis B Surface Antigen

48 Seroprevalence of Hepatitis B Virus and Associated Factors among Health Professionals in University of Gondar Hospital, Northwest Ethiopia

49 A Rare Case of Herpes Simplex Virus-2 Hepatitis with Negative Serology

50 Current progress in the prevention of mother-to-child transmission of hepatitis B and resulting clinical and programmatic implications

51 Comparison of pegylated interferon monotherapy and de novo pegylated interferon plus tenofovir combination therapy in patients with chronic hepatitis B

52 Reactivation of herpesvirus in patients with hepatitis C treated with direct-acting antiviral agents

53 Entecavir monotherapy versus de novo combination of lamivudine and adefovir for compensated hepatitis B virus-related cirrhosis: a real-world prospective multicenter cohort study

54 Prevalence and predictors of occult hepatitis C virus infection among Egyptian patients who achieved sustained virologic response to sofosbuvir/daclatasvir therapy: a multi-center study

55 Prevalence of resistance-associated substitutions to direct-acting antiviral agents in hemodialysis and renal transplant patients infected with hepatitis C virus [Erratum]

56 Declining prevalence of hepatitis C virus among university students in one of the main governorates in Egypt

57 Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant

58 Poor adherence is a contributor to viral breakthrough in patients with chronic hepatitis B

59 Clinical and virological properties of hepatitis C virus genotype 4 infection in patients treated with different direct-acting antiviral agents

60 Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

61 Characterization of hepatitis C virus resistance to grazoprevir reveals complex patterns of mutations following on-treatment breakthrough that are not observed at relapse

62 Sofosbuvir–daclatasvir improves hepatitis C virus–induced mixed cryoglobulinemia: Upper Egypt experience

63 Higher baseline viral diversity correlates with lower HBsAg decline following PEGylated interferon-alpha therapy in patients with HBeAg-positive chronic hepatitis B

64 Serum hepatitis B core antibody levels predict HBeAg seroconversion in chronic hepatitis B patients with high viral load treated with nucleos(t)ide analogs

65 Outcomes and predictors of treatment response with sofosbuvir plus daclatasvir with or without ribavirin in Egyptian patients with genotype 4 hepatitis C virus infection

66 Efficacy and safety of sofosbuvir–ledipasvir for treatment of a cohort of Egyptian patients with chronic hepatitis C genotype 4 infection

67 Prevalence of hepatitis C virus-resistant association substitutions to direct-acting antiviral agents in treatment-naïve hepatitis C genotype 1b-infected patients in western China

68 Detection of hepatitis C virus (HCV) among health care providers in an Egyptian university hospital: different diagnostic modalities

69 Genotyping of HBV and tracking of resistance mutations in treatment-naïve patients with chronic hepatitis B

70 Conceptual framework for outcomes research studies of hepatitis C: an analytical review

71 Influence of host resistance on viral adaptation: hepatitis C virus as a case study

72 Approaches to hepatitis C treatment and cure using NS5A inhibitors

73 Safety and efficacy of entecavir for the treatment of chronic hepatitis B

74 Current treatment of choice for chronic hepatitis C infection

75 New strategies for the treatment of hepatitis C virus infection and implications of resistance to new direct-acting antiviral agents

76 New approaches in the management of chronic hepatitis B: role of tenofovir

77 Decreased hepatocellular carcinoma tumor burden with the achievement of hepatitis C virus sustained virologic response: unlocking the potential of T-cell-mediated immunosurveillance

78 Liver resection versus radiofrequency ablation for hepatitis B virus-related small hepatocellular carcinoma

79 Clinical significance of vascular endothelial growth factor in hepatitis C related hepatocellular carcinoma in Egyptian patients

80 Emerging role of dual antiplatelet therapy in the prevention of hepatitis B virus-associated hepatocellular carcinoma

81 Telaprevir-containing regimen for treatment of hepatitis C virus infection in patients with hepatocellular carcinoma awaiting liver transplantation: a case series

82 Effectiveness and Cost-Effectiveness of Triple Therapy with Telaprevir and Boceprevir for Chronic Hepatitis C: A Decision Analysis from the Brazilian Public Health System Perspective

83 Excellence in Viral Hepatitis Elimination - Lessons from Georgia.

84 The average effective dose of 4-amino-5-(furan-2-yl)-4H-1 ,2,4-triazole-3-thiol in experimental hepatitis

85 Influence of environmental and seasonal factors on microbial contamination levels in clam production areas in southern Tunisia: Escherichia coli, Salmonella spp., hepatitis A virus and norovirus.

86 Effect of Health Insurance on Hepatitis C Sustained Virologic Response Rates to Sofosbuvir-Based Treatment Regimens in a South Florida Community Hospital

87 Innovative strategies for the elimination of viral hepatitis at a national level: a country case series.

88 Frequency of baseline NS5A resistance-associated substitutions in patients infected with genotype 1 of hepatitis C virus in Croatia.

89 Moving towards hepatitis B elimination in Gulf Health Council states: From commitment to action.

90 Clinical factors leading to a change in management in chronic hepatitis B patients managed in a tertiary setting.

91 The change in the nationwide seroprevalence of hepatitis C virus and the status of linkage to care in South Korea from 2009 to 2015.

92 What is the optimal timing of antiviral treatment in pregnant hepatitis B carrier with extremely high viral load?

93 Evaluation of a hepatitis C virus core antigen assay from venepuncture and dried blood spot collected samples: a cohort study.

94 Real-world effectiveness and safety of Ledipasvir/sofosbuvir for genotype 6 chronic hepatitis C patients in Taiwan.

95 Infant follow-up postdelivery from a hepatitis C viral load positive mother

96 The new Xpert HCV viral load real-time PCR assay accurately quantifies hepatitis C virus RNA in serum and whole-blood specimens

97 High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation

98 Tenofovir and telbivudine combination therapy rapidly decreases viral loads in immune-tolerant chronic hepatitis B patients awaiting assisted reproduction: An open-label, randomized, controlled study

99 Challenging hepatitis C-infected liver transplant patients

100 Prevalence of mixed hepatitis C virus (HCV) genotypes among recently diagnosed dialysis patients with HCV infection

101 The Evolution of Hepatitis C Treatment

Keyword Connections

Journals

Research Groups

Bibliographies